Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The combined action of these hormones provides greater efficacy for weight loss and fat metabolism than semaglutide. Average weight loss with tirzepatide is up to 22.5% of body weight in 72 weeks.
Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The combined action of these hormones provides greater efficacy for weight loss and fat metabolism than semaglutide. Average weight loss with tirzepatide is up to 22.5% of body weight in 72 weeks.